A Phase 2 interventional study of AL001 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Alector Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-18.
Sponsored by Alector Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 271st largest by enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2021, is one of 89 in phase 2, and was the 301st registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 33 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
Alector Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Alector Inc. has 2 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.
This is a phase 2 double-blind, placebo-controlled trial to test the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in participants with C9orf72-associated Amyotrophic Lateral Sclerosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AL001 every 4 weeks
Drug: AL001
Placebo every 4 weeks
Drug: Placebo
Administered via intravenous (IV) infusion
Administered via intravenous (IV) infusion
Evaluation of Safety and Tolerability of AL001 Measured by Number of Subjects With Adverse Events
Count of participants with adverse events during the study treatment period
Time frame: 24 weeks
Immunogenicity of AL001
Count of participants positive for Anti-drug Antibodies (ADAs) to AL001 at week 24
Time frame: Week 24
Pharmacokinetics (PK) of AL001 in Serum
Concentration of AL001 in Serum at week 24
Time frame: Week 24
Pharmacokinetics (PK) of AL001 in CSF
Concentration of AL001 in Cerebrospinal fluid (CSF) at week 24
Time frame: Week 24
Change From Baseline in Plasma Progranulin
Evaluate the change from baseline to week 24 in plasma progranulin levels
Time frame: 24 weeks
Change From Baseline in CSF Progranulin
Evaluate the change from baseline to week 24 in Cerebrospinal fluid (CSF) progranulin levels
Time frame: 24 weeks
Change From Baseline in Plasma Neurofilament Light Chain
Evaluate the change from baseline to week 24 in plasma neurofilament light chain levels
Time frame: 24 weeks
Change From Baseline in CSF Neurofilament Light Chain
Evaluate change from baseline to week 24 in Cerebrospinal fluid (CSF) neurofilament light chain levels
Time frame: 24 weeks
| Milestone | AL001 | Placebo |
|---|---|---|
| Started | 3 | 2 |
| Completed | 2 | 2 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Count of participants with adverse events during the study treatment period
| Participants | AL001 | Placebo |
|---|---|---|
| Evaluation of Safety and Tolerability of AL001 Measured by Number of Subjects With Adverse Events | 2 | 2 |
Count of participants positive for Anti-drug Antibodies (ADAs) to AL001 at week 24
| Participants | AL001 | Placebo |
|---|---|---|
| Immunogenicity of AL001 | 1 | 0 |
Concentration of AL001 in Serum at week 24
| ng/mL | AL001 | Placebo |
|---|---|---|
| Pharmacokinetics (PK) of AL001 in Serum | 705792.5 ± 87387.7916 | — |
Concentration of AL001 in Cerebrospinal fluid (CSF) at week 24
| ng/mL | AL001 | Placebo |
|---|---|---|
| Pharmacokinetics (PK) of AL001 in CSF | 547.5 ± 395.2727 | — |
Evaluate the change from baseline to week 24 in plasma progranulin levels
| ng/mL | AL001 | Placebo |
|---|---|---|
| Change From Baseline in Plasma Progranulin | 175 ± 2.8284 | -24.4 ± 9.3338 |
Evaluate the change from baseline to week 24 in Cerebrospinal fluid (CSF) progranulin levels
| ng/mL | AL001 | Placebo |
|---|---|---|
| Change From Baseline in CSF Progranulin | 2.865 ± 1.0677 | -0.385 ± 0.3323 |
Evaluate the change from baseline to week 24 in plasma neurofilament light chain levels
| pg/mL | AL001 | Placebo |
|---|---|---|
| Change From Baseline in Plasma Neurofilament Light Chain | -0.35 ± 3.3234 | 1.9 ± 2.8284 |
Evaluate change from baseline to week 24 in Cerebrospinal fluid (CSF) neurofilament light chain levels
| pg/mL | AL001 | Placebo |
|---|---|---|
| Change From Baseline in CSF Neurofilament Light Chain | 995.5 ± 95.4594 | -1250.5 ± 825.1936 |
Collected over 32 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AL001 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | AL001 | Placebo |
|---|---|---|
| Post lumbar puncture syndromeInjury, poisoning and procedural complications | 2/3 | 1/2 |
| ConstipationGastrointestinal disorders | 0/3 | 1/2 |
| DiarrheaGastrointestinal disorders | 0/3 | 1/2 |
| NauseaGastrointestinal disorders | 0/3 | 1/2 |
| Catheter site irritationGeneral disorders | 0/3 | 1/2 |
| FatigueGeneral disorders | 0/3 | 1/2 |
| Medical device site hemorrhageGeneral disorders | 0/3 | 1/2 |
| PainGeneral disorders | 0/3 | 1/2 |
| PyrexiaGeneral disorders | 0/3 | 1/2 |
| Urinary tract infectionInfections and infestations | 0/3 | 1/2 |
| Age, Categorical(Participants) | AL001 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 4 |
| >=65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | AL001 | Placebo | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | AL001 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 2 | 5 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | AL001 | Placebo | Total |
|---|---|---|---|
| United States | 3 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Oct 2022, 13 months.
Results were first posted in Jun 2025, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Latozinemab
Amyotrophic Lateral Sclerosis →
Alector Inc.